Solvias to Perform Release Testing on World’s First CRISPR-based Gene-Editing Therapy
Global Provider Signs Long-Term Agreement with Vertex Pharmaceuticals for CASGEVY™ Kaiseraugst, Switzerland – January 23, 2024 – Solvias, a global provider of chemistry, manufacturing, and control (CMC) analytics, announced today that it will perform analytical release testing services on the world’s first CRISPR/Cas9 genome-edited cell therapy. The company has signed a long-term agreement with Vertex Pharmaceuticals for CASGEVY™ (exagamglogene […]
Read More
